Alyssa Musso, Pfizer - Qepler Summits And Conferences

Alyssa Musso

Senior Scientist, Drug Safety Research and Development, Global Risk Assessment Services Toxicologist
Pfizer: One of the world's premier biopharmaceutical companies

I received a B.S. in Forensic Science and a B.S. in Chemistry from the University of New Haven in 2013. In 2016, I received a M.S. in Pharmacology and Toxicology from the University of the Sciences in Philadelphia. Following graduate school, I worked as an analytical chemist at Eurofins Lancaster Laboratories for two years and then joined the Analytical Research and Development team at Pfizer in Groton, Connecticut in 2018. In Analytical Research and Development (ARD), I worked as a chemist and performed analytical testing of active pharmaceutical ingredients (APIs), impurities, and intermediates. I also joined a multidisciplinary team in supporting in silico assessments of mutagenic impurities during my time in ARD.

In 2019, I transferred to Drug Safety Research and Development at Pfizer where I worked in Genetic Toxicology, advancing my subject matter expertise in mutagenic impurity assessments and running the exploratory Ames assay. Most recently, in 2022, I began my role as a Global Risk Assessment Services Toxicologist within Drug Safety Research and Development at Pfizer. I continue to support in silico mutagenic impurity assessments in addition to contributing to the development of nitrosamine risk assessments.

Related Sessions:

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 2: Friday, 10 March 2023
CASE STUDY: Expert Review of In Silico Mutagenicity Predictions
  • Case studies demonstrating the different features of review
  • Discrepant in silico predictions and results
  • Assessment of misclassified, unclassified, and out of domain structures
  • Using chemistry rationales for supporting classifications
  • Confirming Ames test results when there are potential risks for false positives or false negatives
View Details